[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SE9802549D0 - Quinoline derivatives - Google Patents

Quinoline derivatives

Info

Publication number
SE9802549D0
SE9802549D0 SE9802549A SE9802549A SE9802549D0 SE 9802549 D0 SE9802549 D0 SE 9802549D0 SE 9802549 A SE9802549 A SE 9802549A SE 9802549 A SE9802549 A SE 9802549A SE 9802549 D0 SE9802549 D0 SE 9802549D0
Authority
SE
Sweden
Prior art keywords
fluoro
chloro
propyl
proviso
hydrogen
Prior art date
Application number
SE9802549A
Other languages
English (en)
Inventor
Anders Bjoerk
Stig Joensson
Tomas Fex
Gunnar Hedlund
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE9802549A priority Critical patent/SE9802549D0/sv
Publication of SE9802549D0 publication Critical patent/SE9802549D0/sv
Priority to NZ508923A priority patent/NZ508923A/xx
Priority to RU2001104342/04A priority patent/RU2213733C2/ru
Priority to ES99933452T priority patent/ES2205854T3/es
Priority to AU49504/99A priority patent/AU751103B2/en
Priority to HU0103224A priority patent/HU229427B1/hu
Priority to PCT/SE1999/001270 priority patent/WO2000003991A1/en
Priority to IL14034699A priority patent/IL140346A0/xx
Priority to IDW20010331A priority patent/ID27423A/id
Priority to APAP/P/2001/002041A priority patent/AP1366A/en
Priority to EP99933452A priority patent/EP1095021B1/en
Priority to YUP-15/01A priority patent/RS50128B/sr
Priority to CNB998085987A priority patent/CN1157378C/zh
Priority to PT99933452T priority patent/PT1095021E/pt
Priority to JP2000560098A priority patent/JP4045070B2/ja
Priority to OA00100011A priority patent/OA11906A/en
Priority to BRPI9912109-3A priority patent/BR9912109B1/pt
Priority to CA002336968A priority patent/CA2336968C/en
Priority to KR10-2000-7014618A priority patent/KR100516382B1/ko
Priority to DK99933452T priority patent/DK1095021T3/da
Priority to CZ20010094A priority patent/CZ300229B6/cs
Priority to MEP-2008-574A priority patent/ME00374B/me
Priority to EEP200100010A priority patent/EE04673B1/xx
Priority to TR2001/00087T priority patent/TR200100087T2/xx
Priority to UA2000127299A priority patent/UA64791C2/uk
Priority to DE69911415T priority patent/DE69911415T2/de
Priority to AT99933452T priority patent/ATE250036T1/de
Priority to PL345388A priority patent/PL199783B1/pl
Priority to IL140346A priority patent/IL140346A/en
Priority to IS5775A priority patent/IS2208B/is
Priority to ZA200007593A priority patent/ZA200007593B/xx
Priority to NO20010211A priority patent/NO317601B1/no
Priority to HR20010039A priority patent/HRP20010039B1/xx
Priority to HK01104765A priority patent/HK1035715A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE9802549A 1998-07-15 1998-07-15 Quinoline derivatives SE9802549D0 (sv)

Priority Applications (34)

Application Number Priority Date Filing Date Title
SE9802549A SE9802549D0 (sv) 1998-07-15 1998-07-15 Quinoline derivatives
PL345388A PL199783B1 (pl) 1998-07-15 1999-07-14 Związki pochodne chinolino-3-karboksyamidu, zawierające je kompozycje farmaceutyczne, sposób ich wytwarzania i ich zastosowanie
BRPI9912109-3A BR9912109B1 (pt) 1998-07-15 1999-07-14 compostos derivados de quinolina, composições farmacêuticas, processo para a manufatura de um composto, e, uso de um composto.
KR10-2000-7014618A KR100516382B1 (ko) 1998-07-15 1999-07-14 퀴놀린 유도체
ES99933452T ES2205854T3 (es) 1998-07-15 1999-07-14 Derivados de quinolina.
CA002336968A CA2336968C (en) 1998-07-15 1999-07-14 Quinoline derivatives
HU0103224A HU229427B1 (en) 1998-07-15 1999-07-14 Quinoline derivatives, process for producing them and pharmaceutical compositions containing them
PCT/SE1999/001270 WO2000003991A1 (en) 1998-07-15 1999-07-14 Quinoline derivatives
IL14034699A IL140346A0 (en) 1998-07-15 1999-07-14 Quinoline derivatives
RU2001104342/04A RU2213733C2 (ru) 1998-07-15 1999-07-14 Производные хинолина, способ их получения (варианты), фармацевтическая композиция и способ лечения с их использованием
APAP/P/2001/002041A AP1366A (en) 1998-07-15 1999-07-14 Quinoline derivatives.
EP99933452A EP1095021B1 (en) 1998-07-15 1999-07-14 Quinoline derivatives
YUP-15/01A RS50128B (sr) 1998-07-15 1999-07-14 Derivati hinolina
CNB998085987A CN1157378C (zh) 1998-07-15 1999-07-14 喹啉衍生物
PT99933452T PT1095021E (pt) 1998-07-15 1999-07-14 Derivados de quinolina
DK99933452T DK1095021T3 (da) 1998-07-15 1999-07-14 Quinolinderivater
OA00100011A OA11906A (en) 1998-07-15 1999-07-14 Quinoline derivatives.
NZ508923A NZ508923A (en) 1998-07-15 1999-07-14 N-phenyl-1-Methyl-2-oxo-quinoline-3-carboxamide derivatives, pharmaceuticals thereof and their use in therapy
AU49504/99A AU751103B2 (en) 1998-07-15 1999-07-14 Quinoline derivatives
IDW20010331A ID27423A (id) 1998-07-15 1999-07-14 Turunan kuinolin
JP2000560098A JP4045070B2 (ja) 1998-07-15 1999-07-14 キノリン誘導体
CZ20010094A CZ300229B6 (cs) 1998-07-15 1999-07-14 Deriváty chinolinu
MEP-2008-574A ME00374B (me) 1998-07-15 1999-07-14 Derivati hinolina
EEP200100010A EE04673B1 (et) 1998-07-15 1999-07-14 Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
TR2001/00087T TR200100087T2 (tr) 1998-07-15 1999-07-14 Kinolin türevleri
UA2000127299A UA64791C2 (en) 1998-07-15 1999-07-14 Quinoline derivatives, a method for the preparation thereof, a pharmaceutical composition and a method for treatment of diseases resulting from pathological inflammation or autoimmunity
DE69911415T DE69911415T2 (de) 1998-07-15 1999-07-14 Chinolinderivate
AT99933452T ATE250036T1 (de) 1998-07-15 1999-07-14 Chinolinderivate
IL140346A IL140346A (en) 1998-07-15 2000-12-14 Quinoline derivatives, pharmaceutical preparations containing them and a process for their preparation
IS5775A IS2208B (is) 1998-07-15 2000-12-18 Quinoline afleiður
ZA200007593A ZA200007593B (en) 1998-07-15 2000-12-18 Quinoline Derivatives.
NO20010211A NO317601B1 (no) 1998-07-15 2001-01-12 Kinolinderivater
HR20010039A HRP20010039B1 (en) 1998-07-15 2001-01-12 Quinoline derivatives
HK01104765A HK1035715A1 (en) 1998-07-15 2001-07-10 Quinoline derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802549A SE9802549D0 (sv) 1998-07-15 1998-07-15 Quinoline derivatives

Publications (1)

Publication Number Publication Date
SE9802549D0 true SE9802549D0 (sv) 1998-07-15

Family

ID=20412093

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9802549A SE9802549D0 (sv) 1998-07-15 1998-07-15 Quinoline derivatives

Country Status (33)

Country Link
EP (1) EP1095021B1 (sv)
JP (1) JP4045070B2 (sv)
KR (1) KR100516382B1 (sv)
CN (1) CN1157378C (sv)
AP (1) AP1366A (sv)
AT (1) ATE250036T1 (sv)
AU (1) AU751103B2 (sv)
BR (1) BR9912109B1 (sv)
CA (1) CA2336968C (sv)
CZ (1) CZ300229B6 (sv)
DE (1) DE69911415T2 (sv)
DK (1) DK1095021T3 (sv)
EE (1) EE04673B1 (sv)
ES (1) ES2205854T3 (sv)
HK (1) HK1035715A1 (sv)
HR (1) HRP20010039B1 (sv)
HU (1) HU229427B1 (sv)
ID (1) ID27423A (sv)
IL (2) IL140346A0 (sv)
IS (1) IS2208B (sv)
ME (1) ME00374B (sv)
NO (1) NO317601B1 (sv)
NZ (1) NZ508923A (sv)
OA (1) OA11906A (sv)
PL (1) PL199783B1 (sv)
PT (1) PT1095021E (sv)
RS (1) RS50128B (sv)
RU (1) RU2213733C2 (sv)
SE (1) SE9802549D0 (sv)
TR (1) TR200100087T2 (sv)
UA (1) UA64791C2 (sv)
WO (1) WO2000003991A1 (sv)
ZA (1) ZA200007593B (sv)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
US6395750B1 (en) * 1999-10-25 2002-05-28 Active Biotech Ab Drugs for the treatment of malignant tumors
AU2003242127A1 (en) * 2002-06-05 2003-12-22 Institute Of Medicinal Molecular Design, Inc. Inhibitors against the activation of ap-1 and nfat
EA011707B1 (ru) * 2002-06-11 2009-04-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения нейродегенеративных заболеваний
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
PT1937642E (pt) 2005-10-19 2014-11-25 Teva Pharma Cristais de sódio de laquinimod, e processos para o fabrico dos mesmos
EP2035001B1 (en) 2006-06-12 2011-11-09 Teva Pharmaceutical Industries Limited Stable laquinimod preparations
WO2008113006A1 (en) * 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
US8178127B2 (en) 2007-12-20 2012-05-15 Teva Pharmaceuticals Industries, Ltd. Stable laquinimod preparations
KR20160079147A (ko) 2008-09-03 2016-07-05 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 2―옥소―1,2―다이하이드로―퀴놀린 조절제
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
AU2010276748A1 (en) 2009-07-30 2012-03-15 Teva Pharmaceutical Industries Ltd. Treatment of Crohn's disease with laquinimod
HUE029983T2 (en) 2009-08-10 2017-04-28 Teva Pharma Treatment of BDNF-related diseases with laquinimod
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
MX337614B (es) 2010-03-03 2016-03-10 Teva Pharma Tratamiento de lupus nefritis usando laquinimod.
KR20130014523A (ko) 2010-03-03 2013-02-07 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 및 메토트렉세이트의 병용에 의한 류마티스 관절염의 치료
KR20130092558A (ko) 2010-07-09 2013-08-20 테바 파마슈티컬 인더스트리즈 리미티드 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도
CN103189357B (zh) * 2010-08-27 2015-11-25 格吕伦塔尔有限公司 作为kcnq2/3调节剂的取代的2-氧代-和2-硫代-二氢喹啉-3-甲酰胺
BR112013007850A2 (pt) 2010-10-14 2016-06-07 Immunahr Ab 1,2-diidro-4-hidróxi-2-oxo-quinolina-3-carboxanilidas como ativadores de ahr
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
AU2012322706A1 (en) 2011-10-12 2014-05-22 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
CN104114172A (zh) 2012-02-16 2014-10-22 泰华制药工业有限公司 N-乙基-n-苯基-1,2-二氢-4,5-二-羟基-1-甲基-2-氧代-3-喹啉甲酰胺、其制备和用途
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療gaba媒介之疾病之拉喹莫德(laquinimod)
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
JP5868839B2 (ja) 2012-12-27 2016-02-24 三菱重工業株式会社 チャー払出管
MX2015011627A (es) 2013-03-14 2016-05-16 Teva Pharma Cristales de laquinimod sodico y proceso mejorado para la elaboracion de los mismos.
KR20170005434A (ko) 2014-04-29 2017-01-13 테바 파마슈티컬 인더스트리즈 리미티드 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드
CN105367492B (zh) * 2014-08-28 2018-07-03 杭州普晒医药科技有限公司 他喹莫德的晶型及其制备方法、其药物组合物和用途
EA030948B1 (ru) 2014-09-23 2018-10-31 Эктив Байотек Аб Хинолинкарбоксамиды для применения в лечении множественной миеломы
PL3180005T3 (pl) 2014-11-19 2018-06-29 Active Biotech Ab Chinolinokarboksyamidy do stosowania w leczeniu białaczki
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
WO2018105943A1 (ko) * 2016-12-07 2018-06-14 순천향대학교 산학협력단 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물
US20230085883A1 (en) 2020-03-03 2023-03-23 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
KR20230043916A (ko) 2020-07-23 2023-03-31 에라스무스 유니버시티 메디컬 센터 로테르담 골수증식성 신생물의 새로운 치료학적 표적으로서 s100 단백질
EP4277628A1 (en) 2021-01-18 2023-11-22 Active Biotech AB Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
US20240285532A1 (en) 2021-05-25 2024-08-29 Active Biotech Ab A plurality of tasquinimod particles and use thereof
KR20240029029A (ko) 2021-07-02 2024-03-05 액티브 바이오테크 에이비 타스퀴니모드를 함유한 약학적 제품 및 이러한 제품의 순도 평가 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
SE469368B (sv) * 1991-10-09 1993-06-28 Kabi Pharmacia Ab Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms)
SE9201076L (sv) * 1992-04-06 1993-10-07 Shimon Slavin Användningen av gamla läkemedel för behandling av diabetes
JPH07224040A (ja) * 1994-02-07 1995-08-22 Fujisawa Pharmaceut Co Ltd キノリン誘導体
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives

Also Published As

Publication number Publication date
CN1157378C (zh) 2004-07-14
HU229427B1 (en) 2013-12-30
NO317601B1 (no) 2004-11-22
IS5775A (is) 2000-12-18
KR20010053115A (ko) 2001-06-25
KR100516382B1 (ko) 2005-09-26
WO2000003991A1 (en) 2000-01-27
HK1035715A1 (en) 2001-12-07
RU2213733C2 (ru) 2003-10-10
CA2336968C (en) 2005-08-30
BR9912109A (pt) 2001-05-02
JP2002520395A (ja) 2002-07-09
PT1095021E (pt) 2003-12-31
ZA200007593B (en) 2001-07-09
ID27423A (id) 2001-04-05
DK1095021T3 (da) 2003-11-24
IL140346A0 (en) 2002-02-10
EP1095021A1 (en) 2001-05-02
HRP20010039B1 (en) 2009-04-30
ES2205854T3 (es) 2004-05-01
EP1095021B1 (en) 2003-09-17
AP1366A (en) 2005-01-26
CZ300229B6 (cs) 2009-03-25
TR200100087T2 (tr) 2001-06-21
AU751103B2 (en) 2002-08-08
IL140346A (en) 2006-07-05
HUP0103224A2 (hu) 2002-01-28
EE04673B1 (et) 2006-08-15
PL345388A1 (en) 2001-12-17
CA2336968A1 (en) 2000-01-27
JP4045070B2 (ja) 2008-02-13
DE69911415D1 (de) 2003-10-23
PL199783B1 (pl) 2008-10-31
EE200100010A (et) 2002-06-17
RS50128B (sr) 2009-03-25
NO20010211L (no) 2001-03-15
NZ508923A (en) 2002-09-27
UA64791C2 (en) 2004-03-15
ATE250036T1 (de) 2003-10-15
BR9912109B1 (pt) 2012-08-21
IS2208B (is) 2007-02-15
CZ200194A3 (en) 2001-05-16
CN1309641A (zh) 2001-08-22
HRP20010039A2 (en) 2001-12-31
AP2001002041A0 (en) 2001-03-31
MEP57408A (en) 2011-05-10
OA11906A (en) 2006-04-10
AU4950499A (en) 2000-02-07
ME00374B (me) 2011-05-10
NO20010211D0 (no) 2001-01-12
DE69911415T2 (de) 2004-07-08
HUP0103224A3 (en) 2002-11-28
YU1501A (sh) 2003-10-31

Similar Documents

Publication Publication Date Title
SE9802549D0 (sv) Quinoline derivatives
SE9801474D0 (sv) Quinoline Derivatives
AP1425A (en) Quinoline derivatives.
TR200000837A2 (tr) Anti-kanser bileşimleri hazırlamak için işlem ve ara maddeler.
ATE37179T1 (de) Dihydropyridazinone.
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
NZ336302A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
CA2205274A1 (en) Novel 2,3 disubstituted-(5,6)-heteroarylfused-pyrimidine-4-ones
BR0213731A (pt) Compostos de silìcio
EA200400219A1 (ru) Производные хинолина и их использование в качестве противоопухолевых средств
ATE216233T1 (de) Indolditerpen alkaloide
EA200101050A1 (ru) Замещенные бензолактамные соединения
DK1082116T3 (da) Anvendelse af 4-piperidinmethanolderivater til behandling af neurologiske sygdomme
MXPA04000615A (es) Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor.
SE0401578D0 (sv) Novel compounds
IT1205640B (it) Nuovi composti ad attivita' antiinfiammatoria,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
ATE56442T1 (de) 2,6-piperazin-dion-derivate, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.
SE0400440D0 (sv) Novel Cinnamic Amides
DK0660840T3 (da) Phosphono-substituerede tetrazolderivater.
ATE264320T1 (de) 5-aminoalkyl- und 5-aminocarbonylsubstituierte indole
MX9601953A (es) Nuevo compesto derivados de 5h-tiazolo [3,2-a] pirimidin-5-ona.
MX9705144A (es) Uso de un compuesto de carboestirilo para preparar un inhibidor de la produccion o secrecion del factor de necrosis tumoral alfa.